PUBLIC CONTRACT · 2017
51001417 - P259-ac-2017- 113 - Aquisição de medicamentos desencadeada pela spms,EPE no âmbito do despacho 1571/b 2016 - E365 - Efavirenz+entricitabina+tenofovir
- Contract value
- €95,294.88
- Signed on
- 3 July 2017
- Procedure
- Ao abrigo de acordo-quadro (art.º 259.º)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 3712909PUBLISHED SUBJECT
51001417 - P259-AC-2017- 113 - AQUISIÇÃO DE MEDICAMENTOS DESENCADEADA PELA SPMS,EPE NO ÂMBITO DO DESPACHO 1571/B 2016 - E365 - EFAVIRENZ+ENTRICITABINA+TENOFOVIR
WHO CONTRACTED
Parties involved
- Place of performance
- Portugal, Portalegre, Elvas; Portugal, Portalegre, Portalegre
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- GILEAD SCIENCES LDA · Tax ID 503604704
HOW MUCH AND WHEN
Values and timeline
- Contract price
- €95,294.88
- Procedure base price
- €95,294.88
- Total effective price
- €23,529.60
- Publication date
- 26 September 2017
- Award date
- 6 June 2017
- Signing date
- 3 July 2017
- Performance period
- 180 days
The contract price is the value agreed in the contract, not the amount paid.
HOW IT WAS CONTRACTED
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Ao abrigo de acordo-quadro (art.º 259.º)
- Award criterion
- Not stated
- CPV code
- 33000000-0 - Equipamento médico, medicamentos e produtos para cuidados pessoais
- Legal basis
- Artigo 259.º do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL 18/2008)
- Framework agreement
- Medicamentos antirretrovíricos para o tratamento da infeção por VIH
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 2929507
KEEP EXPLORING
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.